You can buy or sell LOGC and other stocks, options, ETFs, and crypto commission-free!
LogicBio Therapeutics, Inc. Common Stock, also called LogicBio Therapeutics, is a genome editing company, which engages in developing medicines to treat rare diseases in patients with significant unmet medical need. Read More It focuses on the commercialization of specific genome editing and integration of the therapeutic transgene. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Yahoo FinanceApr 29
LogicBio Therapeutics Receives FDA Orphan Drug Designation for LB-001 for the Treatment of Methylmalonic Acidemia
CAMBRIDGE, Mass., April 29, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to LB-001, a recombinant adeno-associated viral vector with human methylmalonyl-COA mutase (MUT) gene for the treatment of methylmalonic acidemia (MMA). “We are pleased to receive orphan drug designation for ...
-$0.35 per share
-$0.34 per share